Sleep is divided into non-rapid eye movement sleep and rapid eye movement sleep. Non-rapid eye movement sleep has three stages: N1 (light sleep, about 5 percent of total sleep time), N2 (intermediate sleep with sleep spindles and K-complexes, about 50 percent of total sleep time), and N3 (slow-wave or deep sleep, about 15 to 20 percent of total sleep time). N3 is the most physically restorative stage — it is when growth hormone is predominantly secreted and declarative memory consolidation occurs through hippocampal-cortical dialogue. Rapid eye movement sleep, characterized by desynchronized brain activity resembling wakefulness plus skeletal muscle atonia and vivid dreaming, constitutes about 20 to 25 percent of total sleep time and occurs predominantly in the latter half of the night. Rapid eye movement sleep serves emotional memory consolidation and emotional processing functions. Pharmacological suppression of either N3 or rapid eye movement sleep has functional consequences beyond subjective sleep quality, which is why sleep architecture effects of drug classes matter clinically.

Sleep timing and depth are governed by the interaction of two independent processes. Process S (homeostatic sleep pressure) accumulates during wakefulness, driven by progressive buildup of adenosine in the basal forebrain — a byproduct of neuronal energy metabolism. The longer and more intensely one has been awake, the greater the homeostatic sleep drive and the more deep N3 sleep generated at the next sleep onset. During sleep, adenosine is cleared and Process S decays. Caffeine works by competitively blocking adenosine receptors, opposing this homeostatic drive.

Process C (the circadian alerting signal) is generated by the suprachiasmatic nucleus of the hypothalamus — the brain's master circadian clock. It rises throughout the day, peaks in the early evening to maintain wakefulness against rising sleep pressure, then falls sharply to open the circadian gate for sleep onset. The suprachiasmatic nucleus entrains to the light-dark cycle via the retinohypothalamic tract and communicates timing to the body primarily through melatonin secretion from the pineal gland — which is why ramelteon, a melatonin receptor agonist, promotes sleep onset by reinforcing this circadian signal rather than by direct sedation.

The orexin (hypocretin) system provides a third regulatory layer that stabilizes the boundary between wakefulness and sleep. Orexinergic neurons of the lateral hypothalamus are active during wakefulness and provide tonic excitatory drive to all major arousal nuclei — the locus coeruleus (norepinephrine), dorsal raphe (serotonin), tuberomammillary nucleus (histamine), and basal forebrain (acetylcholine). This maintains consolidated wakefulness. During sleep, ventrolateral preoptic area neurons inhibit these arousal nuclei, and reciprocal inhibition between the sleep and wake systems creates a flip-flop switch — generating rapid, stable transitions between states rather than gradual drifts.

Loss of orexinergic neurons in narcolepsy type 1 destabilizes this switch, producing pathological intrusions of sleep into wakefulness (cataplexy, sleep paralysis, hypnagogic hallucinations). Dual orexin receptor antagonists (suvorexant and lemborexant) therapeutically reduce orexin wake-drive to facilitate sleep onset — without broadly suppressing the sleep-generating machinery, which is why they preserve normal sleep architecture.

Tolerance to anxiolytic effects develops over weeks to months of regular use, requiring dose escalation for maintained effect. Physical dependence develops within weeks, producing a withdrawal syndrome that can mimic the original anxiety disorder and complicate both assessment and tapering. Chronic use is associated with cognitive impairment, psychomotor slowing, and — in elderly patients — falls, fractures, and possible dementia association. Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors provide durable anxiolytic effects without tolerance, dependence, or cognitive burden, and are recommended as first-line pharmacotherapy for generalized anxiety disorder, panic disorder, social anxiety disorder, and post-traumatic stress disorder by all major guidelines.